MIRA
Mira Pharmaceuticals Inc
NASDAQ · Pharmaceuticals
$1.20
+0.07 (+6.19%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 15.23M | 13.68M | 17.07M |
| Net Income | 2.05M | 2.22M | 2.28M |
| EPS | — | — | — |
| Profit Margin | 13.5% | 16.2% | 13.3% |
| Rev Growth | +3.2% | +10.2% | +2.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 11.14M | 9.95M | 10.29M |
| Total Equity | 25.74M | 26.89M | 28.51M |
| D/E Ratio | 0.43 | 0.37 | 0.36 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 4.17M | 3.79M | 4.72M |
| Free Cash Flow | 3.12M | 1.71M | 2.33M |